{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Search results for m root_names_stdName in Standardized Name (approximate match)
Status:
Possibly Marketed Outside US
Source:
M003
(2017)
Source URL:
First approved in 2017
Source:
M003
Source URL:
Class:
MIXTURE
Status:
Possibly Marketed Outside US
Source:
21 CFR 352
(2017)
Source URL:
First approved in 2012
Source:
Zithranol by Elorac Inc.
Source URL:
Class:
MIXTURE
Status:
Possibly Marketed Outside US
Source:
M032
(2018)
Source URL:
First approved in 2008
Source:
21 CFR 352
Source URL:
Class:
MIXTURE
Status:
Possibly Marketed Outside US
Source:
21 CFR 333D
(2018)
Source URL:
First approved in 1995
Source:
21 CFR 333E
Source URL:
Class:
MIXTURE
Status:
Possibly Marketed Outside US
Source:
Proactiv MD Ultra-Gentle Cleanser by Alchemee, LLC
(2024)
Source URL:
First approved in 1993
Source:
21 CFR 358H
Source URL:
Class:
MIXTURE
Status:
Possibly Marketed Outside US
Source:
21 CFR 333E
(2001)
Source URL:
First approved in 1975
Source:
ANDA202985
Source URL:
Class:
MIXTURE
Status:
US Approved Rx
(2022)
Source:
BLA761263
(2022)
Source URL:
First approved in 2022
Source:
BLA761263
Source URL:
Class:
PROTEIN
Status:
US Approved Rx
(2021)
Source:
NDA214231
(2021)
Source URL:
First approved in 2021
Source:
NDA214231
Source URL:
Class:
PROTEIN
Targets:
Conditions:
Dasiglucagon (Zegalogue®) is an antihypoglycaemic agent being developed by Zealand Pharma for the treatment of hypoglycaemia, type 1 diabetes mellitus (T1DM) management and congenital hyperinsulinism. Dasiglucagon is a glucagon receptor agonist, which increases blood glucose concentration by activating hepatic glucagon receptors, thereby stimulating glycogen breakdown and release of glucose from the liver. Hepatic stores of glycogen are necessary for dasiglucagon to produce an
antihypoglycemic effect. In March 2021, dasiglucagon received its first approval in the USA for the treatment of severe hypoglycaemia in paediatric and adult patients with diabetes aged 6 years and above. Dasiglucagon, a glucagon analogue, is available as a single-dose autoinjector or prefilled syringe for subcutaneous injection.
Status:
US Approved Rx
(2021)
Source:
BLA761195
(2021)
Source URL:
First approved in 2021
Source:
BLA761195
Source URL:
Class:
PROTEIN
Status:
US Approved Rx
(2005)
Source:
BLA125118
(2005)
Source URL:
First approved in 2005
Source:
BLA125118
Source URL:
Class:
PROTEIN
